UBX1325 For DME: Phase 2 Data

Dante Pieramici, MD

Show Description +

Dr. Pieramici shares data from the phase 2 BEHOLD and phase 2b ASPIRE trials of a novel senolytic candidate, UBX1325 (Unity Bio), for the treatment of diabetic macular edema.

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

UBX1325

•

Diabetic macular edema, DME

•

Clinical Trials

•

BEHOLD

•

ASPIRE

•

senolytic

•

Unity Bio

Up Next

Name: UBX1325 For DME: Phase 2 Data
Uploaded: 2025-08-06T18:56:26+00:00
Description: Dr. Pieramici shares data from the phase 2 BEHOLD and phase 2b ASPIRE trials of a novel senolytic candidate, UBX1325 (Unity Bio), for the treatment of diabetic macular edema.

Switching Agents in DME

Michael Javaheri, MD

Treating Underrepresented Patients With DME

Andres Emanuelli, MD

Treating DR with OTX-TKI

Katherine E. Talcott, MD

An Oral Option for Stargardt Disease: New Data

Kenneth C. Fan, MD, MBA

Optogenetics for RP: 126-Week Data

David S. Liao, MD, PhD

ILM Flaps: 10 Years of Data

Zofia A. Nawrocka, MD, PhD

When to Treat with Pegcetacoplan

Roger A. Goldberg, MD, MBA

Treatment Burden: EYP-1901 Versus Aflibercept

Avni P. Finn, MD, MBA

Pharmacodynamics of ABBV-RGX-314

Robert L. Avery, MD

The PDS Versus Anti-VEGF Injections in the Fellow Eye

Jordan Graff, MD, FACS

Back to All Videos

UBX1325 For DME: Phase 2 Data

Dante Pieramici, MD

Dr. Pieramici shares data from the phase 2 BEHOLD and phase 2b ASPIRE trials of a novel senolytic candidate, UBX1325 (Unity Bio), for the treatment of diabetic macular edema.

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

UBX1325

•

Diabetic macular edema, DME

•

Clinical Trials

•

BEHOLD

•

ASPIRE

•

senolytic

•

Unity Bio

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

UBX1325 For DME: Phase 2 Data

Up Next

UBX1325 For DME: Phase 2 Data

More From ASRS: 2025 Coverage